See more : Toyo Gosei Co.,Ltd. (4970.T) Income Statement Analysis – Financial Results
Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Sema4 Holdings Corp. (SMFRW) Income Statement Analysis – Financial Results
- Horizon Construction Development (9930.HK) Income Statement Analysis – Financial Results
- Liberty Live Group (LLYVK) Income Statement Analysis – Financial Results
- West Coast Paper Mills Limited (WSTCSTPAPR.NS) Income Statement Analysis – Financial Results
- D. B. Corp Limited (DBCORP.BO) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
Corgenix Reports First Quarter Fiscal 2014 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results. The report disclosed that the company achieved record operating results for the quarter ended...
Corgenix Files Concurrent de novo 510(k) Pre-Market Notification for FDA Clearance of its Hyaluronic Acid (HA) Test Kit
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today it has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for...
Study: Aspirin Ineffective in 20 Percent of Heart Disease Patients
DENVER--(BUSINESS WIRE)--A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin. Corgenix Medical Corporation, developers of the AspirinWorks® Test for aspirin effect, said the study adds more...
Corgenix to Host Conference Call to Discuss First Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company’s financial and operating performance for its quarter...
Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would...
Corgenix Reports Fiscal 2013 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal year Form 10-K and reported financial results. The report disclosed that the Company’s operating results have continued to advance for the...
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company’s financial and operating performance for its fiscal...
Corgenix Medical Corporation Announces New AtherOx® (Oxidized LDL Technology) License and Cooperation Agreement
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx® License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of...
Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with Bank of the West. The new revolving line of...
Corgenix Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners ELITech Group and AXA Diagnostics at the AACC Clinical Lab Expo 2013 in Houston, Texas. Corgenix will exhibit its AspirinWorks®...
Source: https://incomestatements.info
Category: Stock Reports